R A Charlton1, S Jordan2, A Pierini3, E Garne4, A J Neville5, A V Hansen4, R Gini6, D Thayer7, K Tingay7, A Puccini8, H J Bos9, A M Nybo Andersen10, M Sinclair11, H Dolk12, L T W de Jong-van den Berg9. 1. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. 2. Department of Nursing, College of Human and Health Sciences, Swansea University, Swansea, UK. 3. Institute of Clinical Physiology - National Research Council (IFC-CNR), Pisa, Italy. 4. Paediatric Department, Hospital Lillebaelt, Kolding, Denmark. 5. IMER (Emilia Romagna Registry of Birth Defects), Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy. 6. Agenzia Regionale di Sanità Della Toscana, Florence, Italy. 7. Centre for Health Information, Research and Evaluation, Swansea University, Swansea, UK. 8. Drug Policy Service, Emilia Romagna Region Health Authority, Bologna, Italy. 9. Pharmacoepidemiology and Pharmacoeconomics Unit, Department of Pharmacy, University of Groningen, Groningen, the Netherlands. 10. Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 11. Maternal, Fetal and Infant Research Centre, University of Ulster, Ulster, UK. 12. Institute of Nursing, University of Ulster, Ulster, UK.
Abstract
OBJECTIVE: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population-based databases. DESIGN: Descriptive drug utilisation study. SETTING: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK. POPULATION: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010. METHODS: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non-UK) in the year before, during or in the year following pregnancy. MAIN OUTCOME MEASURES: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period. RESULTS: In total, 721 632 women and 862,943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6%; 95% confidence interval (CI95 ), 9.4-9.8%] and lowest in Emilia Romagna (3.3%; CI95 , 3.2-3.4%). During pregnancy, SSRI prescribing had dropped to between 1.2% (CI95 , 1.1-1.3%) in Emilia Romagna and 4.5% (CI95 , 4.3-4.6%) in Wales. The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK. CONCLUSIONS: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.
OBJECTIVE: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population-based databases. DESIGN: Descriptive drug utilisation study. SETTING: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK. POPULATION: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010. METHODS: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non-UK) in the year before, during or in the year following pregnancy. MAIN OUTCOME MEASURES: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period. RESULTS: In total, 721 632 women and 862,943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6%; 95% confidence interval (CI95 ), 9.4-9.8%] and lowest in Emilia Romagna (3.3%; CI95 , 3.2-3.4%). During pregnancy, SSRI prescribing had dropped to between 1.2% (CI95 , 1.1-1.3%) in Emilia Romagna and 4.5% (CI95 , 4.3-4.6%) in Wales. The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK. CONCLUSIONS: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.
Authors: Anthony Wemakor; Karen Casson; Ester Garne; Marian Bakker; Marie-Claude Addor; Larraitz Arriola; Miriam Gatt; Babak Khoshnood; Kari Klungsoyr; Vera Nelen; Mary O'Mahoney; Anna Pierini; Anke Rissmann; David Tucker; Breidge Boyle; Lolkje de Jong-van den Berg; Helen Dolk Journal: Eur J Epidemiol Date: 2015-07-07 Impact factor: 8.082
Authors: Lindsey A Sjaarda; Jeannie G Radoc; Kerry S Flannagan; Sunni L Mumford; Keewan Kim; Neil J Perkins; Robert M Silver; Enrique F Schisterman Journal: Fertil Steril Date: 2020-10-14 Impact factor: 7.329
Authors: Luca Degli Esposti; Carlo Piccinni; Diego Sangiorgi; Andrea Fagiolini; Stefano Buda Journal: Clin Drug Investig Date: 2015-11 Impact factor: 2.859